Colorectal cancer (CRC) is the third most common cause of cancerrelated deaths worldwide.
Several new studies are ongoing with the aim of finding the best combinations of cytotoxic and targeted therapies and to validate novel biomarkers able to predict sensitivity/resistance to specific anticancer agents. In this article we review some of the strategies aimed at improving the efficacy of drug therapies in human CRC.
The Combination of 5-fluorouracil and Irinotecan in Human Colorectal Carcinoma
Doublet chemotherapy (i.e. fluoropyrimidines combined with IRI or l-OHP) represents the standard of care for the treatment of metastatic CRC, since it has been demonstrated to increase the time to progression and overall survival rates. However, while most of the schedules combining l-OHP and FU differ only marginally, the combinations of IRI and FU are characterised by major differences in terms of doses and schedules. [3] [4] [5] 11, 12 Indeed, regardless of the specific combination regimen, FU/IRI-based chemotherapy achieves a response rate of 30-50% and an overall survival period of 14-20 months in advanced CRC. 
Integration of Traditional Chemotherapeutic Regimens with Molecular-targeted Agents
The combination of cetuximab or panitumumab with IRI-or l-OHPbased chemotherapy was proved to increase response rate and prolong progression-free survival in the first-line treatment of patients with metastatic CRC. 27 Furthermore, the inhibition of the EGFR1 pathway results in the restoration of the sensitivity to IRI or l-OHP by restoring mechanisms of chemoresistance.
7,27
Recently, several groups have shown that activating mutations in the K-RAS protein, which partially transduces the activation signal from EGFR1, abrogates the therapeutic effect of anti-EGFR1 therapy.
28-30
These results have restricted the use of anti-EGFR1 to the set of patients with wild-type K-RAS tumours. However, selection of patients on the basis of K-RAS status is not perfect. While the test for nonresponse is highly specific (nearly 95% of patients with somatic mutations of K-RAS fail to respond to anti-EGFR1 therapy), 40-60% of patients with wild-type K-RAS fail to respond to the treatment. 31 This suggests that there are other important molecular determinants of response that have yet to be determined. The identification of these predictive biomarkers of the response to anti-EGFR1 agents represents a major strategy for tailoring treatments on the molecular profile of each tumour in order to improve patient outcomes and reduce toxicities.
Angiogenesis, the formation of new blood vessels from pre-existing vessels, allows tumours to absorb nutrients and oxygen for their further growth, and helps cancer cells to access the systemic circulation and establish metastases. The switch to an angiogenic phenotype is caused by an increased production of pro-angiogenic factors, including VEGF and basic and acidic fibroblast growth factor (FGF), and a decrease in angiogenic inhibitors. 32 VEGF is a specific mitogen for the endothelial cell and acts as a survival factor through the inhibition of apoptosis, also playing an important role in mobilising endothelial cell precursors to sites of angiogenesis (see Figure 1B) . 33 VEGF is upregulated in most human tumours, including CRC. 33 Bevacizumab is an anti-VEGF humanised monoclonal antibody and is the most advanced agent of its class in clinical development.
Several studies have examined bevacizumab in combination with chemotherapy in first-and second-line settings in patients with metastatic CRC. Indeed, the addition of bevacizumab to FU/l-OHP-or FU/IRI-based chemotherapy results in a significantly longer survival time, greater overall response rate, longer duration of response and longer progression-free survival in metastatic CRC. 34, 35 It is noteworthy that, at present, there are no molecular determinants predictive of the response to anti-angiogenic therapies.
Drug Resistance in Colorectal Carcinoma
Drug resistance is a multifactorial phenomenon involving multiple inter-related or independent pathways, including changes in cellular responses, such as increased cell ability to repair DNA damage or tolerate stress conditions and acquiring mechanisms for escaping apoptosis. 36 Most heat shock proteins (HSPs) have strong cytoprotective effects and have been characterised as molecular chaperones, proteins with the property of modifying the structures and interactions of other proteins. 37 The levels of HSPs are elevated in Novel Strategies to Improve the Efficacy of Anticancer Agents in Human Colorectal Carcinoma many cancers, and HSP over-expression results in a poor prognosis in terms of survival and response to therapy in specific cancer types. 38 Elevated HSP expression in malignant cells plays a key role in protection from the spontaneous apoptosis associated with malignancy, as well as the apoptotic cell death induced upon drug therapy, mechanisms that may underlie the role of HSPs in tumour progression and drug resistance. 38, 39 At a molecular level, the cytoprotective activity of HSPs can be explained in several ways: as molecular chaperones they can more efficiently repair the damaged proteins resulting from cytotoxic drug administration, protect cancer cells from apoptosis 40 and enhance DNA repair. 41 HSPs are considered potential targets for anticancer therapy.
Due to our specific scientific interest in the functional characterisation of the mitochondrial HSP TNF-receptor-associated protein 1 (TRAP1), especially its role in chemo-resistance, we conclude our discussion by presenting a recently identified role of the TRAP1/HSP90 pathway in cell survival and drug resistance and its potential role as antiapoptotic mechanism in CRC. 42 A major advance in the knowledge of mitochondrial HSP TRAP1 function was demonstrated by recent results suggesting that TRAP1 and HSP90 are components of a mitochondrial survival pathway that is selectively activated in tumour cells and is responsible for antagonising the pro-apoptotic activity of cyclophilin D (CypD), thus favouring mitochondria integrity and cell survival. 42 The disruption of TRAP1/HSP90 interaction, using the mitochondriadirected ATP-binding peptidomimetic shepherdin, induces CypD release and the consequent opening of the mitochondrial pore (see Figure 2 ). This finding correlates with several other observations that suggest that HSP90 is involved in favouring resistance to antiblastic agents in human tumours. It has been proposed that, because of its restricted repertoire of client proteins, mainly kinases and signalling molecules, HSP90 occupies a critical role in cellular homeostasis. 43, 44 HSP90 chaperones are, indeed, required for the activity of several key regulators of apoptosis and through these associations may confer survival advantages to tumour cells. 43 A derivative of geldanamycin, 17AAG, has been proposed for clinical use in cancer patients due to its ability to block the HSP90 pathway by binding the regulatory pocket in the N-terminal domain of HSP90. 45 17AAG has shown a significant antitumour activity in vitro and in animal models, and thus has entered clinical testing in cancer patients. 46 Early evidence of therapeutic activity has been described in human solid tumours by using 17AAG alone or in combination with paclitaxel. 47 However, recent reports suggest that 17AAG is unable to accumulate in mitochondria: 42, 48 hence, HSP90 inhibition as well as cytochrome-c release cannot occur and therefore apoptosis is not activated. 
